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Abstract
There is increasing evidence of the close relationship between persistent activa-
tion of the glutaminergic pathway, central sensitization, hyperalgesia and chronic 
pain. Opioids have long  been the standard analgesics used in the perioperative. 
However, their side effects, namely  opioid-induced hyperalgesia, opioid tolerance 
and post-operative dependence in patients with chronic pain that are to undergo 
aggressive surgeries have motivated anesthesiologists to develop alternative 
anesthetic techniques. They include analgesic and anti-inflammatory drugs that 
act by modulating the nociceptive pathways with an opioid-sparing effect and 
even opioid-free anesthesia (OFA). In OFA plus postoperative analgesia (OFAA) 
techniques, ketamine plays a fundamental role as an analgesic with its antagonist 
action on the N-Methyl-D-Aspartate-receptors (NMDAr). However, ketamine is 
limited to use at sub-anesthetic doses (“low-doses”) due to its dose-dependent 
side effects. Consequently, other analgesic drugs with anti-NMDAr effects like 
magnesium sulfate and other non-opioid analgesics such as lidocaine and alpha-
2-adrenergic agonists are often used in OFAA techniques. The aim of this text is 
to present a summary of the importance of the use of ketamine in OFA based on 
nociceptive pathophysiology. Additionally, the perioperative protocol (OFAA) 
with the anti-hyperalgesic approach of ketamine, lidocaine and dexmedetomidine 
co-administration in our center will be described. Some of the main indications for 
the OFAA protocol will be mentioned.
Keywords: Opioid-free anesthesia, OFA, Opioid-free anesthesia and analgesia, 
OFAA, minimizing-opioid-use, NMDA-receptors antagonists,  
ketamine-magnesium-lidocaine-dexmedetomidine-methadone, anti-hyperalgesia, 
central sensitization, opioid intolerance, opioid-induced hyperalgesia, 
craneocervical/thoracic fixation, complex spine surgery
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1. Introduction
Nociceptive phenomena associated with surgical trauma involve local and 
systemic inflammatory processes, activation of cellular and humoral immune 
mechanisms, and adrenergic and neuroendocrine activation. The activation of the 
glutaminergic pathway plays a determining role in secondary sensitization at the 
level of the central nervous system, which is responsible for nociceptive amplifica-
tion, persistence of postoperative pain, and hyperalgesia.
Strategies to reduce perioperative opioid consumption and its consequent side 
effects have been based on the use of multimodal analgesia schemes. The develop-
ment of opioid-free anesthesia (OFA) techniques, indicated for particular patient 
populations in which opioids may be harmful, requires the use of drug mixtures in 
which NMDA receptors (NMDAr) antagonists are integral. The most clinically used 
NMDAr inhibitors in anesthesia are ketamine and magnesium sulfate. Their co-
administration in OFA techniques has synergistic analgesic effects. The concomitant 
use of intravenous lidocaine and dexmedetomidine provides additional benefits 
to the use of NMDAr antagonists to reduce the central sensitization phenomenon 
(SC), hyperalgesia and opioid-induced hyperalgesia (OIH).
2.  NMDAr are involved in nociception even from the beginning of 
tissue trauma: peripheral hyperalgesia is an event modulated by a 
glutamatergic system in the dorsal root ganglia (DRG)
The nociceptive pathway undergoes important functional changes and modulation 
under surgical trauma (tissue damage and inflammation). This plasticity is mediated 
by many mechanisms, including peripheral and central sensitization. The paramount 
element for these modificationsis the result of release of many chemical mediators 
peripherally as well as neurotransmitters in the spinal cord and the brain [1].
Peripheral sensitization contributes to increased afferent stimulation of the spi-
nal cord. It is mediated by many processes in which nerve tissues and immune cells 
act under a complex barrage of pain-mediating substances. The nociceptive impulse 
generated by an inflammatory event in peripheral tissue is regulated in the dorsal 
root ganglia (DRG) by a system that involves satellite glial cells and glutamatergic 
NMDA receptors (NMDAr) [2].
Mechanical inflammatory nociceptor sensitization is dependent on glutamate 
release in the DRG and subsequent NMDAr activation in satellite glial cells. That fact 
supports the idea that peripheral hyperalgesia is an event modulated by a glutama-
tergic system in the DRG. Moreover, retrograde sensitization of the primary sensory 
neuron has been proposed as an essential mechanism for induction and maintenance 
of peripheral inflammatory hyperalgesia. It has been suggested that this phenom-
enon is due to the release of glutamate in the spinal cord, which acts retrogradely on 
NMDARs present at the presynaptic terminals of the primary sensory neuron [3–5].
In summary, numerous receptors and ion channels are involved. Continued 
increased input to the spinal cord results in further central sensitizing changes.
3.  What is the importance of glutaminergic pathway in the nociceptive 
process and secondary sensitization during surgical trauma?
The glutamate receptor NMDAr is the starting pointof secondary sensitiza-
tion and the amplification of pain. Hence, the NMDAr may be a potential target 
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for analgesic therapy in the context of opioid-free anesthesia and postoperative 
analgesia (OFAA).
The primary sensitization resulting from local inflammation of the tissue under 
surgical trauma activates the “asleep afferent” thereby increasing the total nocicep-
tive afferent signals to the spinal cord, which is the beginning of the development 
of the central sensitization. The excitatory amino acid glutamate plays a central role 
both via the α-amino-3-hydroxy-5- methyl-4-isoxazolepropionate (AMPA) ion-
channel linked receptor in acute pain transmission and via the N-methyl-d-aspartate 
(NMDA) receptor to mediate sensitizing effects. In the acute state, the NMDAr 
are limited by a voltage-dependent magnesium ion block of the channel. Increased 
afferent input from primary sensitization releases the magnesium ions and activates 
theNMDA receptors. NMDAr activation increases intracellular calcium flux and 
enhances the activation of the second-order neuron. The increase in intracellular 
calcium also stimulates cyclooxygenase, lipoxygenase and protein-kinases [2, 6].
Surgical stimulus activates C fibers and generatesa progressive build-up in the 
amplitude of response in dorsal horn neurons andbrings onthe Wind-up phenom-
enon, which is a specific initiator of central sensitization [1].
4.  How does the glutaminergic pathway mediate the persistence of pain 
after surgery and chronic pain?
Neuropeptides like substance P and the calcitonin gene-related peptide (CGRP), 
released from primary afferent neurons, contribute to the activation of the NMDAr 
in pain states. Neuropeptides such as neurokinin A and B act on NK receptors and 
activate the NMDAr directly by inducing decreased potassium ion conductance 
and phosphorylation-induced increases of intracellular calcium, facilitating 
central sensitization and hyperalgesia. Brain-derived neurotrophic factor (BDNF) 
is produced by nerve growth factor (NGF)-dependent nociceptors and increases 
the glial inflammation. Moreover, BDNF augments spinal neuron excitability by 
phosphorylation-mediated stimulation of the NMDAr.
Finally, longer-term changes of central sensitization may be explained by 
transcriptional changes.
Hence, the significance ofthe spinal cord as a location for an anti-hyperalgesic 
approach leads us consider the important role the NMDA receptors have in central 
sensitization and their potential usefulness as a focus of analgesic therapeu-
tics [7, 8].
Ketamine and magnesium sulfate are the most frequently used NMDAr antago-
nist drugs in anesthesia. Ketamine in association with lidocaine and dexmedeto-
midine infusions have led to the development of opioid-free anesthetic techniques 
(OFA). Moreover, the combination of low doses of ketamine with these adjuvant 
medications have shown an important opioid-sparing effect on postoperative pain 
control and has an additional anti-hyperalgesic effect [8].
5. Why should opioid use be minimized during the perioperative period?
Intravenous opioids are the commonly used analgesics during general anesthesia 
along with hypnotic drugs. Opioids provide potent analgesia, attenuate the neuro-
endocrine response triggered by surgery, and provide hemodynamic stability. 
However, these drugs have side effects like nausea, vomiting, decreased intestinal 
peristalsis, respiratory depression, histamine release and opioid-induced hyperalge-
sia mediated by NMDAr stimulation [6].
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Multimodal postoperative analgesia has been the gold standard for more than 
20 years. It makes for opioid-sparing and better outcomes than with drugs like 
morphine that are administered as a sole analgesic agent after surgery. OFA is based 
on the association of drugs and/or techniques that makes for good quality general 
anesthesia with no need for opioids. The association can combine NMDAr antago-
nists (ketamine, lidocaine, magnesium sulfate), sodium channel blockers (local 
anesthetics), anti-inflammatory drugs (NSAID, dexamethasone, lidocaine) and 
alpha-2 agonists (dexmedetomidine, clonidine) [9].
There is a group of patients in whom opioid use is relatively contraindicated. 
It is comprised of those with gastrointestinal intolerance susceptible to develop-
ing intestinal ileus, functional bladder disorders, a history of severe nausea and 
vomiting, sleep apnea syndrome, morbid obese, patients with mast cell activation 
syndrome (MCAS), autonomic symptoms like postural orthostatic tachycardia syn-
drome (POTS), patients with chronic pain, chronic fatigue syndrome and myalgic 
encephalomyelitis, patients with high-dose opioid use, opioid tolerance, opioid-
induced hyperalgesia (OIH) and patients who are prone to drug dependence [9–13].
The above patients benefit from OFAA techniques. When feasible, the use of 
regional anesthesia is helpful. Then again, the substitution of opioids for analgesic 
drugs with different mechanisms of action is desirable when general anesthesia is 
indicated [14, 15].
6.  Ketamine, magnesium, lidocaine and dexmedetomidine: an  
anti-hyperalgesic combination
Ketamine plays a fundamental role in OFA techniques since it is a potent NMDAr 
inhibitor that provides an excellent analgesic effect at sub-anesthetic doses. Since 
ketamine can cause dose-dependent side effects (cardiovascular excitation, halluci-
nations, psychomimetic events, nausea and vomiting as well as hyper-salivation), it 
is advisable to associate it with other NMDAr antagonists like magnesium sulfate or 
dextromethorphan to enhance its analgesic effect with lower doses.
Ketamine and magnesium have been widely described as improving postopera-
pain control. The literature has consistently reported that both drugs provide 
effective postoperative analgesia and a reduction in opioid consumption. A meta-
analysis that aggregated data from 2482 patients showed that intravenous ketamine 
reduces postoperative opioid use by 40% [16]. Similar results have been shown with 
the administration of intravenous magnesium [17–19].
Furthermore, experiments on the association of ketamine and magnesium may 
give us an important clue as to the useful of the association. In fact, pretreatment 
with ketamine has been demonstrated to improve the anti-nociceptive effect of 
magnesium [20]. Interestingly, myocardial and endothelial cells express NMDA 
receptor. Thus, a synergistic effect can be expected on the NMDA receptor in the 
cardiovascular system with the resulting cardiovascular stability by the competitive 
blocking actions of drugs [21, 22].
On the other hand, there are many publications that describe the use of intravenous 
lidocaine as a systemic analgesic with particular attenuating effects on the intraopera-
tive inflammatory reaction at multiple levels (i.e., reduction of inflammatory bio-
markers by direct action on cell membrane of monocytes, neutrophils and mast cell, 
PKC-mediated reduction of Ca++ intracellular influx and K+A-channels, action over 
cholinergic, adrenergic, GABAergic, NMDAr, and NK-1r pathways, etc.). Lidocaine 
has a non-relevant analgesic effect mediated by Na+-channel blocks at therapeutic 
plasmatic concentrations [10, 23, 24].
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Additionally, lidocaine modulates the immune response to surgical trauma with 
benefits in term of cancer recurrence. So, it is advisable to associate the intravenous 
infusion of lidocaine along with dexamethasone plus non-steroidal anti-inflam-
matory drugs (NSAIDs) to complement the analgesic effect of NMDA antagonists 
through the reduction of inflammation due to surgical trauma. Moreover, it has been 
shown that the intravenous lidocaine reduces the requirements for hypnotic drugs 
(propofol or sevoflurane) and has a dose-dependent anti-NMDAr effect [25–31].
Dexmedetomidine is an alpha-2 adrenergic agonist which acts at different levels 
of the nociceptive pathway like on the peripheral nerves, pre-synaptic receptors 
at the dorsal horn of the spinal cord and at the supraspinal level (Locus Coeruleus). 
The association of dexmedetomidine with OFA may provide additional benefits. 
They encompass the attenuation of the sympathetic nervous system, a reduction in 
intraoperative catecholamines release, a decrease in the requirements for hypnotics 
(propofol or inhalation anesthetics) due to its sedative effects, decreases in the post-
operative psychomimetic side-effects of ketamine, the prevention of postoperative 
delirium and shivering [32, 33].
Meta-analyses have shown that clonidine and dexmedetomidine provide analge-
sia with an added opioid-sparing effect and PONV reduction [34, 35].
The authors has been using the OFAA protocol on patients with a medical 
history of postoperative nausea and vomiting, ERAS protocols in complex laparo-
scopic surgery that include bariatric surgery and patients with chronic pain, opioid 
treatment and OIH who are to undergo extensive/complex spinal surgery. The 
outcomes of our patients have undergone complex gastro-intestinal surgery have 
been consistent with the published literature. An important reduction in nausea and 
vomiting (20%), a faster recovery from intestinal peristalsis, adecrease in ileus and 
acute gastric remnant dilatation, and a reduction in the post-operative use of opioid 
rescue (30%) have been recorded in our case-series [36–38].
7.  Is it feasible to provide a perioperative management focusing on  
anti-hyperalgesia and central sensitization for patient with chronic 
pain who are to undergo major spinal surgery?
Patients with severe spinal deformities like scoliosis, and cranio-cervical-tho-
racic instability due to connective tissue defects and Joint Hypermobility Syndrome 
often suffer from widespread chronic pain and hyperalgesia. In patients with Joint 
Hypermobility Syndrome (JHS) who developed cranio-cervical instability (CCI), 
both severe craniocervical pain and widespread pain (i.e., somatic/neuropathic/vis-
ceral), have multi-factorial causes, that are strongly related to chronic nociceptive 
neuro-inflammation, glial activation and neuronal plasticity in the spinal cordas 
well as in the brainstem and brain that lead to a common final pathway, which is the 
Central Sensitization phenomena (CS) [7, 10].
Furthermore, many patients with CCI, JHS, chronic fatigue and severe chronic 
pain receive different types of opioids, which further complicates pain due to OIH. 
Sometimes, these patients may suffer from a category of pain known as central 
intractable pain. It is a painful condition that does not respond to opioids and their 
use may even be detrimental to the patient [6, 7].
Therefore, considering the probable mechanisms of the chronic pain (CS and 
OIH) that affect patients with JHS and CCI as well as their frequent association with 
MCAS and POTS, the use of opioids in total intravenous anesthesia (TIVA) during 
occipitocervical~thoracic fixation (OCF) was halted in our practice. Intra-operative 
opioid-based analgesia has been replaced by infusions of lidocaine, ketamine, 
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magnesium, dexmedetomidine and propofol as hypnotic [10, 39]. As stated before, 
they are coadjuvants with known anti-hyperalgesic properties. This OFAA protocol 
aims at improving postoperative pain control, minimizing postoperative opioid 
rescues and reducing preoperative opioid doses in those patients who have been 
prescribed those drugs over a long period (Figure 1).
Infusions of lidocaine, ketamine and dexmedetomidine are continued at lower 
doses during the post-operative period (for a maximum of one week) as part of a 
multimodal analgesia plan [10, 39]. The continued perioperative use of a lidocaine, 
ketamine and dexmedetomidine infusion and the gradual reduction of the doses 
over one week might overcome the peak of the inflammatory surgical-response. 
Therefore, its effect on pain and Central Sensitizationis to minimize opioid expo-
sure and result in a reduction of VAS [8, 39–43].
In a case-series study of 42 patients with JHS that have undergone OCF [39], the 
authors found a lower VAS in the OFA group in the postoperative time (p < 0.001). 
The reduction in the VAS was more significanton the 1st postoperative day in the 
OFA group 5.35 (4.83–5.86) vs. the Opioid group (OP) 7.89 (7.56–8.23) (p < 0.001), 
meaning up to 32% decrease in the VAS of the OFA group. TheVAS at hospital- 
discharge was lower in the OFA group: 4.96 (4.54–5.37) vs. OP group: 6.39 
(6.07–6.71) (p < 0.001). The methadone requirement was lower in the OFAgroup 
(p < 0.001). No methadone rescue was needed with 78% (IC 95%)of patients in 
OFA group. On the contrary, 95% (IC95%) in the OP group needed methadone 
rescue at high doses. The OFA group showed decreased ileus, nausea and vomit-
ing (p < 0.001). Compared with preoperative values, there were decreased opioid 
Figure 1. 
Opioid-free anesthesia and analgesia (OFAA) vs. opioid based anesthesia and analgesia (OP) protocols for 
patients with joint hypermobility syndrome undergoing craneo-cervical fixation. Adapted from Ramírez-
Paesano C., et al. [39].
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requirements for 60.9% in the OFA group at hospital-discharge. A 77% reduction of 
anxiolytics requirements was also seen. In the OFA group, 17.4% (n = 4) of patients 
had visual hallucinations. Haloperidol was used in two patients [39].
The doses of lidocaine, ketamine, magnesium and dexmedetomidine proposed 
in the author’s protocol seems to be a combination with balanced anti-nociceptive 
synergism. It coincides with recent publications that describe lidocaine, ketamine, 
dexmedetomidine and MgSO4 as the best options in both obese patients and 
complex spine surgery [23, 44].
According to the literature, there is more consensus on the benefits of OFA use in 
bariatric surgery or complex laparoscopy surgery. In term of the reduction of postop-
erative opioid requirements and a better recovery, the controversies that surround 
the benefits of OFA in major spinal surgery may be due to the diversity of surgical-
procedures, the varying degrees of complexity of the cases and the exceptionally 
varied use of coadjuvants for post-operative multi-modal analgesia. However, there 
is strong evidence that opioid-inclusive anesthesia does not reduce postoperative 
pain but is associated with more side effects in comparison with the opioid minimiz-
ing approach. OFA management should be evaluated on a case-by-case basis.
With the current evidence, OFA management could not be confirmed as an 
independent factor in reducing postoperative pain in all the surgical settings in 
which it has been used. However, OFA management plus postoperative use of 
lidocaine, ketamine, and dexmedetomidine infusions (OFAA) as part of robust 
multimodal analgesia may explain the results seen in patients with extensive chronic 
pain, hyperalgesia and Central Sensitization phenomena [10, 39, 45, 46].
8. Is it possible to use some opioid as postoperative rescue in OFAA?
Many times patients undergoing extensive surgery require postoperative opioids as 
rescue for breakthrough pain control. The OFAA protocol used in our hospital includes 
methadone as rescue for severe postoperative pain [10, 39]. We believe that methadone 
is the most suitable opioid to use as rescue analgesic for severe pain due to its anti-
MNDAr effect. Methadone decreases OIH and attenuates the central sensitization 
phenomenon. It also has a reducing effect on the reuptake of serotonin and norepi-
nephrine. All these mechanisms of action make methadone a suitable opioid for use in 
OFAA protocols. In addition, the use of methadone with ketamine (both anti-NMDAr) 
shows a “boosting” and synergistic effect that enhances the opioid-sparing effect [47].
Recent publications have recommended the use of methadone (0.15–0.2 mg/
kg bolus) at the start of anesthetic induction in complex spinal surgery [48]. 
Methadone has been shown to provide a postoperative opioid-sparing effect and 
improved pain control. These benefits appear to persist for months after surgery 
compared to other opioids such as morphine or hydromorphone [49].
A recent meta-analysis confirms the benefits of methadone use at the onset of 
anesthesia in extensive and painful surgeries [50, 51].
9. Are there some contraindications to the use of OFAA?
We should be noted that OFAA is no applicable to all patients. OFAA is relatively 
contraindicated in patients with node blocks, autonomous nervous system disfunc-
tions including orthostatic hypotension as seen in patients with multiple systemic atro-
phy disease. Furthermore, OFAA should not be administered to patients with coronary 
stenosis or acute coronary isquemia as well as patients with hemodynamic instability, 
increased intracranial pressure or polytrauma. The peripheral vasodilation caused by 
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OFAA which could limit the perfusion of vital organs [52]. Finally, OFAA should not 
be administered to patients who have known allergies to some of its components.
10.  What can be found in the literature on the risks and benefits of OFAA?
There is uncertainty in the literature on the balance between OFA benefits and 
risks. Some systematic reviews have shown an improvement in the incidence of 
postoperative pain, nausea and vomiting [53]. However, alpha-2-receptor agonists 
such as Dexmedetomidine or clonidine may be responsible of some side effects such 
as hypotension, bradycardia and sedation. Therefore, the safety of OFAA has been 
questioned [53–55]. The authors have not observed the aforementioned complica-
tions with the use of dexmedetomidine, probably because we did not administer 
starting boluses, and the maintenance doses used were limited to 0.2–0.3 mcg/kg/h.
A Meta-Analysis of randomized controlled trials including 2209 participants 
comparing OFAA to opioid based anesthesia (OBA) found no clinically significant 
effect of OFA on acute pain and opioid use after surgery in a large sample of studies. 
However, it found clinically important reductions in postoperative nausea, vomit-
ing, shivering and sedation incidence showing a beneficial impact on postoperative 
patient comfort [56]. Definitive evidence-based conclusions related to the use of 
OFAA are still lacking. For this reason, it is important to continue exploring how to 
prevent its side effects as well as possible alternatives.
11. Conclusion
The activation of the glutaminergic pathway plays a determining role in second-
ary sensitization at the level of the central nervous system, which is responsible for 
nociceptive amplification, persistence of postoperative pain, and hyperalgesia.
The development of opioid-free anesthesia techniques, indicated for particular 
patient populations in which opioids may be harmful, requires the use of drug 
mixtures in which NMDAr antagonists are essential.
The most clinically used NMDA receptor inhibitors in anesthesia are ketamine 
and magnesium sulfate. They are the cornerstone to reduce or avoid the SC phe-
nomenon, hyperalgesia and OIH in the surgical setting. Their co-administration in 
OFA techniques has synergistic analgesic and anti-hyperalgesic effects. The con-
comitant use of intravenous lidocaine and dexmedetomidine provides additional 
benefits to the use of NMDAr antagonists.
The authors consider that OFA has precise indications. However, the use of 
regional anesthetic techniques (whenever possible) or the use of intravenous mix-
tures with anti-hyperalgesic and opioid-sparing effects should be used, ifpossible, 
in patients with a history of chronic pain or with central sensitization phenomena 
and hyperalgesia who are to undergo extensive and very painful surgeries. Finally, 
methadone is a suitable opioid for use in modified OFAA protocols because its anti-
NMDAr action and opioid-sparing effect.
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